2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (eular/era–edta) recommendations for the management of lupus nephritis

existing therapies and disease monitoring
►
Calcineurin inhibitor efficacy in non- Asian patients.
►
B- cell targeting therapies (eg, belimumab, combination of 
rituximab and belimumab, obinutuzumab) and cytokine 
inhibitors in lupus nephritis.
►
Imaging for kidney fibrosis.
►
Duration and withdrawal of therapy.
►
Damage accrual in long- term disease.
►
Protocolised repeat biopsies: value of early (vs late) repeat 
biopsy.
►
Non- immune mechanisms in progression of lupus nephritis, 
such as hypertension, obesity, dyslipidaemia.
►
Impact of patient education programs.
►
Role of eculizumab in antiphospholipid syndrome- associated 
nephropathy.